超顺磁性氧化铁标记神经干细胞移植入局灶性脑缺血大鼠纹状体的MRI示踪及其对学习记忆的影响

目的 探讨以超顺磁性氧化铁（SPIO）标记的胎鼠神经干细胞（NSCs）移植入局灶性脑缺血大鼠纹状体的MRI示踪及其对学习与记忆的影响。方法 体外培养的胎鼠NSCs用Fe2O3-多聚左旋赖氨酸（Fe2O3-PLL）标记，普鲁士蓝和台盼蓝染色分别检测标记率和细胞活力。将大鼠随机分为A组（正常对照组）、B组（正常标记NSCs移植组）、C组（脑缺血组）、D组（标记NSCs移植组）、E组（未标记NSCs移植组）及F组（灭活标记NSCs移植组）。取C组、D组、E组和F组大鼠制备局灶性脑缺血模型；将标记及未标记的NSCs悬液及灭活的标记NSCs悬液分别定向注射于B组、D组、E组和F组大鼠左侧纹状体内；移植后3d、7d、2周、3周、4周，对A组、C组、D组和E组分别进行Y型电迷宫检测；对B组、D组和F组进行活体MRI示踪扫描；MRI扫描后的大鼠行脑组织切片普鲁士蓝染色，观察移植的NSCs分布。结果NSCs的FeO3-PLL标记率近100％，标记的NSCs细胞活力为95％。与C组比较，D组和E组移植后各时间点大鼠的学习与记忆能力明显改善（均P〈0.05）；MRI显示移植4周后D组移植区低信号影范围较大；脑组织切片可见移植的NSCs沿胼胝体向对侧迁移。结论 Fe2O3-PLL标记不影响NSCs活力；移植NSCs能改善脑缺血大鼠的学习与记忆功能；移植的NSCs可向病灶区迁移。     

Ganglioside AGF2 promotes task-specific recovery and attenuates the cholinergic hypofunction induced by AF64A

Ganglioside AGF2 attenuated both the cognitive impairments and the cholinergic hypofunction induced by ethylcholine aziridinium ion (AF64A). Adult male rats were initially trained to perform a standard radial arm maze (RAM) task. Following training, they were injected intraperitoneally with 10 mg/kg AGF2 (AF/AGF2, CSF/AGF2) or the saline vehicle (AF/SAL, CSF/SAL) for 3 days prior to and for 14 days following bilateral injection of AF64A (3 nmol/side) or artificial CSF into the lateral ventricles. AF64A (AF/SAL) impaired performance of the standard RAM task and a working memory version of the task in which various delays were imposed between the fourth and fifth arm choices. In contrast, animals that received AGF2 and AF64A (AF/AGF2) were initially impaired on the standard RAM task but rapidly recovered and were performing as well as the control groups (CSF/SAL, CSF/AGF2) by the end of training. The AF/AGF2 group, however, exhibited persistent deficits on the working memory version of the RAM task. These data demonstrate that AGF2 promotes behavioral recovery in a task-dependent manner in this model system. Neurochemical analysis revealed that AF64A produced a significant 37% decrease in hippocampal ChAT activity that was significantly attenuated, but not prevented, by prior treatment with AGF2. Thus the behavioral recovery afforded by AGF2 might be related to increased cholinergic activity in the hippocampus that is sufficient for the performance of tasks which either lack or have a minimal working memory component. An analysis of the temporal profile of AGF2-induced neurochemical recovery revealed that ChAT activity was enhanced at 20, but not 2 or 11, weeks following AF64A. Since AGF2 did not attenuate the cholinergic cell loss (35%) induced by AF64A in the medial septum these data indicate that AGF2 might have (1) enhanced sprouting of cholinergic terminals following the initial insult, (2) directly increased ChAT activity in surviving neurons, or (3) induced behavioral and neurochemical recovery through a combination of these or other mechanisms.     

Low molecular weight glycosaminoglycan C3 attenuates AF64A-stimulated, low-affinity nerve growth factor receptor-immunoreactive axonal varicosities in the rat septum

Glycosaminoglycans (GAGs) play a pivotal role in the pathogenesis of Alzheimer's disease (AD). Although, as we have shown earlier, a low molecular weight GAG, C3, protects against ethylcholine aziridinium (AF64A)-induced cholinergic damage, and against A(beta)-induced tau-2-immunoreactivity (IR), the mechanism of the neuroprotective effect of GAGs is not yet known. Several clues exist. Previous studies in rats revealed that continuous NGF infusion (icv) after AF64A injection increases septal ChAT and AChE activities. Moreover, C3 increases axonal outgrowth in the rat hippocampus, raising the possibility of a NGF-receptor mediated neuroprotection. Furthermore, it has been reported that NGF expression is increased in the septum following AF64A administration. To study the question regarding the mechanism of neuroprotective action of GAGs, AF64A, a selective cholinotoxin, was administered stereotaxically, bilaterally, into the lateral ventricles of Fischer albino male rats (1 nmol/2 microl/side). In order to establish the effect of C3 on the expression of the NGF receptor-IR elements, C3 was administered orally (25 mg/kg, once a day), by gavage, 7 days before, and 7 days after the AF64A injection. NGF receptor immunohistochemistry revealed that AF64A induced the appearance of NGF-receptor-IR axonal varicosities in the rat medial septum. These varicose fibers were attenuated by 14 days' administration of C3. The possible explanation of our data may be that C3 increases NGF synthesis in the lateral septum. The increased level of NGF could suppress the increased, AF64A-induced NGF receptor expression in the medial septal nucleus. These results further accentuate our earlier observations that C3 may have potential as a therapeutic agent in AD and other neurodegenerative disorders.     

Human neural stem cells genetically modified to overexpress brain‐derived neurotrophic factor promote functional recovery and neuroprotection in a mouse stroke model

Intracerebral hemorrhage (ICH) is a lethal stroke type; mortality approaches 50%, and current medical therapy against ICH shows only limited effectiveness, so an alternative approach is required, such as stem cell‐based cell therapy. Previously we have shown that intravenously transplanted human neural stem cells (NSCs) selectively migrate to the brain and promote functional recovery in rat ICH model, and others have shown that intracerebral infusion of brain‐derived neurotrophic factor (BDNF) results in improved structural and functional outcome from cerebral ischemia. We postulated that human NSCs overexpressing BDNF transplanted into cerebral cortex overlying ICH lesion could provide improved survival of grafted NSCs and increased angiogenesis and behavioral recovery in mouse ICH model. ICH was induced in adult mice by injection of bacterial collagenase into striatum. The HB1.F3.BDNF (F3.BDNF) human NSC line produces sixfold higher amounts of BDNFF over the parental F3 cell line in vitro, induces behavioral improvement, and produces a threefold increase in cell survival at 2 weeks and 8 weeks posttransplantation. Brain transplantation of human NSCs overexpressing BDNF provided differentiation and survival of grafted human NSCs and renewed angiogenesis of host brain and functional recovery of ICH animals. These results indicate that the F3.BDNF human NSCs should be of great value as a cellular source for experimental studies involving cellular therapy for human neurological disorders, including ICH. © 2010 Wiley‐Liss, Inc.     

Recent preclinical evidence advancing cell therapy for Alzheimer's disease

Alzheimer's disease (AD) causes brain degeneration, primarily depleting cholinergic cells, and leading to cognitive and learning dysfunction. Logically, to augment the cholinergic cell loss, a viable treatment for AD has been via drugs boosting brain acetylcholine production. However, this is not a curative measure. To this end, nerve growth factor (NGF) has been examined as a possible preventative treatment against cholinergic neuronal death while enhancing memory capabilities; however, NGF brain bioavailability is challenging as it does not cross the blood-brain barrier. Investigations into stem cell- and gene-based therapy have been explored in order to enhance NGF potency in the brain. Along this line of research, a genetically modified cell line, called HB1.F3 transfected with the cholinergic acetyltransferase or HB1.F3.ChAT cells, has shown safety and efficacy profiles in AD models. This stem cell transplant therapy for AD is an extension of the neural stem cells' use in other neurological treatments, such as Parkinson's disease and stroke, and recently extended to cancer. The HB1 parent cell and its associated cell lines have been used as a vehicle to deliver genes of interest in various neurological models, and are highly effective as they can differentiate into neurons and glial cells. A focus of this mini-review is the recent demonstration that the transplantation of HB1.F3.ChAT cells in an AD animal model increases cognitive function coinciding with upregulation of acetylcholine levels in the cerebrospinal fluid. In addition, there is a large dispersion throughout the brain of the transplanted stem cells which is important to repair the widespread cholinergic cell loss in AD. Some translational caveats that need to be satisfied prior to initiating clinical trials of HB1.F3.ChAT cells in AD include regulating the host immune response and the possible tumorigenesis arising from the transplantation of this genetically modified cell line. Further studies are warranted to test the safety and effectiveness of these cells in AD transgenic animal models. This review highlights the recent progress of stem cell therapy in AD, not only emphasizing the significant basic science strides made in this field, but also providing caution on remaining translational issues necessary to advance this novel treatment to the clinic.     

AF64A (ethylcholine aziridinium ion), a cholinergic neurotoxin, selectively impairs working memory in a multiple component T-maze task

The present study examined the nature of the cognitive deficits associated with a selective decrease of cholinergic activity in the hippocampus. Male Fischer rats were trained to perform a multiple component T-maze task which simultaneously assessed their ability to perform on the basis of trial-specific information (working memory) and trial-independent information (reference memory). Following 125 acquisition trials rats were bilaterally injected with AF64A (3 nmol/side) or artificial CSF into the lateral ventricles and allowed 14 days to recover before behavioral testing resumed. The controls rapidly returned to their preoperative level of performance on both components of the maze task. AF64A-treated animals were transiently impaired on the reference memory task. Their performance rapidly improved and they were performing at preoperative levels within 4 days of testing. In contrast, these animals exhibited a marked and long-lasting impairment in their performance of the working memory component. After behavioral testing was completed, neurochemical analysis revealed that AF64A produced a significant decrease in choline acetyltransferase (ChAT) activity in the hippocampus (43%) 42 days following surgery. This dosing regimen produced no alterations of striatal or cortical ChAT activity. These data suggest that alterations of hippocampal cholinergic activity severely impair an animal's ability to perform working memory tasks.     

Septohippocampal adaptive GABAergic responses by AF64A treatment

A cholinergically disrupted laboratory animal has been produced by administration of the cholinotoxin ethylcholine aziridinium mustard (AF64A), which produced a dysfunction in the cholinergic forebrain system. After AF64A treatment, a reduction of choline acetyl transferase (ChAT) activity was measured in the hippocampal regions. ChAT activity was preferentially reduced in tissue samples of the dorsal with respect to the ventral hippocampus, and concomitantly with this reduction, a compensatory increase in ChAT activity in the medial septum was found. Tissue gamma‐aminobutyric acid (GABA) content in the hippocampal and septal brain areas was not affected by AF64A, indicating a specific effect on the cholinergic septohippocampal projection. The rate of GABA accumulation induced by aminooxyacetic acid administration was higher in the dorsal hippocampus and medial septum of AF64A‐treated animals, but not in their ventral hippocampus and lateral septum, where significant changes occurred in ChAT activity. Concomitantly with the changes in GABA metabolism, a significant B_max increase and K_d reduction of ³H‐flunitrazepam binding in the hippocampus of AF64A‐treated animals were associated with changes in the ChAT activity. This finding suggests an increase of GABA input on the cholinergic somas of the medial septum and an uncompensated GABAergic interneuron activity in the hippocampus. In this study, we present an adaptive mechanism of homotypic compensatory metabolism by cholinergic somas, and a heterotypic response of the GABAergic septohippocampal projection system, which was elicited by AF64A administration. J. Neurosci. Res. 55:178–186, 1999. © 1999 Wiley‐Liss, Inc.     

Immunohistochemical evidence for degeneration of cholinergic neurons in the forebrain of the rat following injection of AF64A-picrylsulfonate into the dorsal hippocampus

The cholinergic neurotoxin, AF64A-picrylsulfonate, was unilaterally infused into the dorsal hippocampus of Wistar rats (2 nmol/2 μl/4 min; A 6.2, L^s 1.5, H 6.5, Paxinos and Watson). After 19 days the animals' brains were processed for immunohistochemical staining of choline acetyltransferase (ChAT). Morphometry and counting of ChAT-immunoreactive profiles revealed shrinkage and disappearance of cholinergic neurons in the medial septum and diagonal band of Broca at the lesioned brain side. These data indicate a retrograde degeneration of cholinergic neurons following injection of AF64-A-picrylsulfonate into the dorsal hippocampus of the rat.     

APP/PS1双转基因小鼠早期记忆功能障碍与胆碱能系统的关系研究

目的观察转APP/PS1基因阿尔茨海默病小鼠(APP/PS1小鼠)早期空间学习记忆功能及乙酰胆碱能系统的变化以及两者之间的相关性,探讨阿尔茨海默病早期学习记忆障碍的发病机制。方法应用Morris水迷宫法评定3月龄APP/PS1小鼠及相应野生型(WT)小鼠的空间学习记忆功能;采用免疫组织化学及组织化学染色方法检测脑组织中β-淀粉样蛋白(Aβ)斑块沉积情况;采用ELISA法检测脑组织中乙酰胆碱(ACh)含量以及胆碱乙酰转移酶(ChAT)和乙酰胆碱酯酶(AChE)活性,并探讨小鼠脑组织中ACh含量与其空间记忆能力、ChAT活性的相关性。结果水迷宫评定结果显示两组小鼠到达平台的潜伏期无统计学差异(P>0.05);APP/PS1小鼠在目标象限的游泳时间百分比〔(29.02±4.27)%〕和距离百分比〔(28.85±3.77)%〕较WT小鼠均下降(P<0.05)。APP/PS1小鼠脑组织中尚无Aβ斑块的沉积。APP/PS1小鼠脑组织中ACh含量〔(45.23±1.40)ng/g prot〕和ChAT活性〔(279.53±12.13)U/g组织湿重〕均较WT小鼠〔分别为(54.08±4.84)ng/gprot、(315.84±11.32)U/g组织湿重〕显著降低(P<0.05),两组小鼠脑组织中AChE活性无统计学差异(P>0.05)。小鼠脑组织中ACh含量与其空间记忆功能(目标象限航行时间百分比、目标象限航行路程百分比)呈正相关(r=0.861、r=0.874,P<0.05),ACh含量与ChAT活性呈正相关(r=0.926,P<0.05)。结论 APP/PS1小鼠空间记忆功能障碍、ACh含量减少和ChAT活性降低可发生于Aβ斑块沉积之前。脑组织中ACh含量减少和ChAT活性降低可能与APP/PS1小鼠记忆功能损害密切相关。     

Cholinergic neurotoxicity induced by ethylcholine aziridinium (AF64A) in neuron-enriched cultures

The sequence of events in neuronal changes induced by the cholinotoxin ethylcholine aziridinium (AF64A) was studied. Neuron-enriched cultures derived from 8-day-embryonic chick cerebra were treated with AF64A at concentrations of 10(-5), 10(-4) and 10(-3) M. Choline acetyltransferase (ChAT) was used as an index of cholinergic neurons. Changes in cell morphology, the immunocytochemical and biochemical presence of ChAT, and DNA and protein content were assessed. Neuron-enriched cultures exposed to AF64A showed a dose-dependent response; after 24 h of exposure to 10(-3) M toxin all cells were dead, whereas a concentration of 10(-5) M did not alter culture morphology or DNA and protein contents. Despite the lack of cytological changes and the presence of ChAT immunoreactivity, biochemically assessed ChAT activity was reduced 36% in 10(-5) M treated cultures. Thus, the implicated decrease in acetylcholine synthesis in these cells cannot entirely account for the neuronal degeneration. Simultaneous exposure of cultures to both AF64A and 10 times higher concentrations of choline chloride delayed or diminished the neurotoxic changes. The protective effect of high choline concentrations was interpreted as evidence of competition between choline and AF64A for the high affinity choline transport system and as constituents in the cell membrane. Examination of the temporal sequence of cytotoxic changes in 10(-4) M exposed cultures revealed that disruption of neuronal aggregates and fragmentation of neurites occurred between 4 and 8 hours of exposure. After 24 h, some neurons survived but with attenuated arbors; in contrast, astrocytes appeared intact, suggesting that glial cells are more resistant than neurons to the toxic effects of AF64A. These findings suggest this culture model may be useful to further elucidate the mechanisms of AF64A drug action and study differentiation of cultured neuronal populations in the absence of cholinergic cells.     

bFGF and heparin but not laminin are necessary factors in the mediums that affect NSCs differentiation into cholinergic neurons

OBJECTIVES: Neural stem cells (NSCs) are self-renewed, pluripotent cells that can differentiate into neurons, astrocytes and oligodendrocytes. Cholinergic neurons are an important kind of neurons that play an essential role in the treatment of Parkinsonism and epilepsy. We are interested in how different mediums affect NSCs differentiation into cholinergic neurons. METHODS: NSCs were isolated from the striatum corpora of embryonic brain in a 14-day pregnant rat. Cells were cultured in basic mediums [F12/DMEM (1:1) including 1% B27 (v/v) and 20 ng/ml EGF] but with different combinations of three supplements: bFGF (20 ng/ml), heparin (5 mug/ml) and laminin (1 mug/ml). After 7 days culturing, cells were immunized with choline acetyltransferase (ChAT), a marker enzyme of cholinergic neuron. RESULTS: We found ChAT could not be detected in the basic mediums with only one supplement. Then, we tested the combination of two out of three. We found that ChAT positive cells could only be detected in the medium with bFGF and heparin (FH). However, when we added the laminin into the FH, more ChAT positive cells appeared. DISCUSSION: This finding suggests that bFGF and heparin are essential in the mediums that affect NSCs differentiation into cholinergic neurons, and laminin is an important positive factor in this process.     

Chronic brain cytochrome oxidase inhibition selectively alters hippocampal cholinergic innervation and impairs memory: prevention by ladostigil

A 25-35% reduction of brain cytochrome oxidase (COx) activity found in Alzheimer's disease (AD) could contribute to neuronal dysfunction and cognitive impairment. The present study replicated the reduction in brain COx activity in rats by administering sodium azide (NaN(3)) for 4 weeks via Alzet minipumps at the rate of 1 mg/kg/h, and determined its effect on hippocampal cholinergic transmission, spatial and episodic memory. NaN(3) caused a selective reduction in choline acetyltransferase (ChAT) immunoreactivity in the diagonal band, a major source of cholinergic input to the hippocampus and cingulate cortex, without altering the number of cholinergic neurons. NaN(3) also induced a significant increase in vesicular acetylcholine transporter (VAChT)-immunoreactive varicosities, GAP-43 in the subgranular layer and of transferrin receptors (TfR) in the hilus of the dentate gyrus. These neurochemical changes were associated with impairment in spatial learning in the Morris water maze and in episodic memory in the object recognition test. Chronic treatment with ladostigil, a novel cholinesterase and monoamine oxidase inhibitor, prevented the decrease in ChAT in the diagonal band, the compensatory increase in synaptic plasticity and TfR and the memory deficits without restoring COx activity. Ladostigil had no significant effect on ChAT activity, synaptic plasticity or TfR in control rats. Ladostigil may have a beneficial effect on cognitive deficits in AD patients that have a reduction in cortical COx activity and cholinergic hypofunction.     

乙酰胆碱特征超低频经颅磁刺激对阿尔茨海默病模型大鼠记忆力的影响

目的探索乙酰胆碱特征超低频经颅磁刺激(ACh-TMS)对阿尔茨海默病(AD)模型大鼠学习记忆力的影响及其机制。方法 SD大鼠随机分为正常组(N组)、模型组(M组)、假手术组(P组)、假刺激组(M+P组)、乙酰胆碱特征超低频磁刺激组(ACh-TMS组)和多奈哌齐组(donepezil组),每组10只。双侧海马注射Aβ1-42建立AD模型。Morris水迷宫实验观察大鼠学习记忆力。检测海马组织脑源性神经营养因子(BDNF)及乙酰胆碱(ACh)含量、乙酰胆碱酯酶(AChE)及胆碱乙酰转移酶(Ch AT)活力变化。改良Highman刚果红法观察淀粉样物质沉积情况。结果与M+P组比较,ACh-TMS组大鼠平均逃避潜伏期缩短、目标象限游泳时间百分比及跨越平台次数明显增多(P0.05);BDNF、ACh含量及Ch AT活力显著提高(P0.05)。除N组和P组外,其余各组大鼠海马区可见淀粉样物质沉积。结论 ACh-TMS可改善AD模型大鼠学习记忆力,其机制可能与提高中枢胆碱能递质含量、促进海马BDNF表达有关。     

Involvement of the septohippocampal cholinergic system in representational memory

To develop an animal model for testing muscarinic agonists, we examined the effects of cholinergic lesions with the ethylcholine aziridinium ion (AF64A) on two types of memory tasks. The tasks provided a distinction between representational and dispositional memory that could be measured in a single paradigm. Young, male Long-Evans rats were trained in a modified T-maze to learn both a discrimination task and a paired-run alternation task. Once animals learned the tasks, they were administered either saline or AF64A (5 nmol into each hippocampus) via stereotaxic technique. One week following surgery, saline-treated animals exhibited comparable performances (P greater than 0.2) on both the discrimination task (90.0 +/- 2.6% correct) and the alternation task (79.5 +/- 5.7%). In contrast, animals treated with AF64A showed a significant impairment of performance (P less than 0.005) on the alternation task (56.1 +/- 1.7%) as compared to the discrimination task (81.6 +/- 5.0%). Performance of the alternation task was significantly lower for AF64A-treated animals than for controls (P less than 0.02). AF64A-treated animals subsequently injected with pilocarpine (1.0 mg/kg, i.p.) showed moderate improvements in performance on the alternation task, while performance on the discrimination task remained unaffected. Immunocytochemical studies of choline acetyltransferase (ChAT) and tyrosine hydroxylase (TH) immunoreactivity indicated a loss of ChAT-positive cells in the septal region in AF64A-injected animals while TH-positive cells in the ventral tegmental area were unaffected by the treatment. The data suggest that AF64A can be used to produce selective lesions of the septohippocampal cholinergic system, which plays a greater role in representational memory than in dispositional memory.(ABSTRACT TRUNCATED AT 250 WORDS)     

Dose-dependent effect of cholinotoxin AF64A on the cholinergic elements of the cingulum bundle in rat

Previous studies revealed that cholinergic neurons possessing long axons are extremely sensitive to ethylcholine aziridinium ion (AF64A) administration [Neuropharmacology 31 (1992) 397]. In the present paper we examined the effect of AF64A on the cholinergic elements of the cingulum bundle. Seven days after AF64A administration choline acetyltransferase (ChAT)-immunoreactive fibers were extensively damaged on the dorsal part of cingulum bundle. These findings are the first reporting damage by AF64A to this brain region.     

痴呆大鼠模型的行为学、脑内胆碱乙酰转移酶及突触素改变

目的：观察Meynert核损害对大鼠脑内胆碱乙酰转移酶(ChAT)和突触素(P38)的影响。方法：Ibotenic acid定位损伤大鼠脑建立AD模型，利用水迷宫和跳台观察其行为学改变，利用原位杂交、免疫组化及图像分析测定大鼠脑内胆碱乙酰转移酶(ChAT)和突触素的表达。结果：胆碱能损害组大鼠的学习记忆能力低于正常对照组和假手术组，其脑内ChAT和突触素的表达也明显下降。结论：保护中枢胆碱能系统和增加突触素水平有助于改善认知记忆能力。     

Effects of repeated administration of (−)-nicotine on AF64A-induced learning and memory impairment in rats

Summary. It has been reported that pretreatment with (−)-nicotine prevents glutamate- and amyloid beta protein (Aβ)-induced cytotoxicity in vitro. However, few studies on the neuroprotective effects of (−)-nicotine in vivo have been reported. We examined whether repeated administration of (−)-nicotine exhibits neuroprotective effects in AF64A-treated rats. (−)-Nicotine (0.1 and 0.2 mg/kg, s.c.) was administered once a day for 28 days. On day 14, AF64A (2.5 nmol/side) was injected bilaterally into the hippocampus. Intrahippocampal injection of AF64A showed severe impairment of learning and memory in rats in the water maze and passive avoidance tests. Repeated administration of (−)-nicotine (0.1 and 0.2 mg/kg, s.c.) did not reverse the impairment of memory induced by AF64A in the water maze test. Interestingly, the (−)-nicotine (0.1 and 0.2 mg/kg, s.c.)-treated group showed weak impairment of learning and memory after AF64A treatment compared to the (AF64A + saline)-treated group in the passive avoidance test. These results suggested that (−)-nicotine may have neuroprotective effects against the neurotoxicity induced by AF64A. Received March 1, 2001; accepted April 30, 2001     

Contrasting patterns of protein phosphorylation in human normal and Alzheimer brain: focus on protein kinase C and protein F1/GAP-43.

We introduce a new procedure to study kinase substrates in postmortem human brain. By adding purified exogenous protein kinase C (PKC) and the phospholipid phosphatidylserine to brain homogenates in vitro we are able to analyze PKC substrates. A human 53-kDa phosphoprotein is described that appears to be homologous to rat and monkey protein F1 (GAP-43). This identity is based on molecular weight, isoelectric point, phosphorylation by exogenous protein kinase C, enhancement of its phosphorylation by three activators (phospholipids, calcium and phorbol esters), phosphopeptide maps, and cross-reactivity with an antibody raised against rat protein F1. Protein F1 is a PKC substrate associated with synaptic plasticity and nerve growth. Its phosphorylation in rat brain has been correlated with long-term potentiation, an electrophysiological model of memory. In the present study of normal brain, human protein F1 shows an occipitotemporal in vitro phosphorylation gradient. This is consistent with previous observations in nonhuman primates. This gradient is less pronounced in Alzheimer's disease (AD). Changes in the in vitro phosphorylation pattern of three other non-PKC substrates in Alzheimer's disease, including one with characteristics similar to microtubule-associated protein tau, are also reported. These results suggest that protein phosphorylation can be studied in postmortem human brain and that PKC-mediated phosphorylation of protein F1, already linked to synaptic plasticity and memory, may be altered in AD.     

神经干细胞与雪旺细胞共移植后对阿尔茨海默病大鼠行为学及脑组织形态学的影响

目的探讨神经干细胞与雪旺细胞共移植后对阿尔茨海默病（AD）大鼠行为学及脑组织形态学的影响。方法建立AD大鼠模型,分别将神经干细胞、神经干细胞与雪旺细胞以及等量的生理盐水注入AD模型大鼠脑内。1个月后,与正常组一起进行morris水迷宫实验观察实验大鼠学习记忆能力的改变。35d后,处死实验鼠,通过HE染色观察各组实验鼠脑组织形态学改变。结果细胞移植后AD大鼠的学习记忆能力明显改善,与生理盐水对照组相比差异显著（P＜0．01）,具有统计学意义。共移植组表现最为明显,与正常组相比无明显差异（P＞0．05）。与生理盐水对照组相比神经干细胞移植后海马与额叶受损细胞的恢复明显减轻,以共移植组的改变尤为明显,其形态学表现接近于正常组。结论雪旺细胞与神经干细胞共移植后AD大鼠的学习记忆能力增强,脑组织病理改变减轻,学习记忆能力明显改善,对AD大鼠的治疗作用优于神经干细胞单独移植组。     

Glycosaminoglycan C3 protects against AF64A-induced cholinotoxicity in a dose-dependent and time-dependent manner

Several studies revealed that proteoglycans (PGs) and glycosaminoglycans (GAGs) play a pivotal role in the pathogenesis of Alzheimer's disease (AD). PGs have affinity to amyloid beta (Abeta) and protect it against proteolysis, and the consequent aggregation is the cause of neurotoxicity. This effect is believed to be attenuated by GAGs. Moreover, a low-molecular-weight GAG C3 derived from unfractionated heparin has been reported to protect against Abeta-induced tau-2 immunoreactivity and cholinergic damage induced by a cholinotoxin, AF64A, in rat. However, the optimal dose and the timeframe of administration of C3 are still unknown. In our studies, we revealed the concentration-dependent and time-dependent effects of C3 on AF64A-induced cholinergic lesion in rat. C3 was administered orally in 5, 10, and 25 mg/kg/day concentration, 7 days before and/or 7 days after intracerebroventricular (i.c.v.) AF64A administration. Our results have shown that 25 mg/kg/day C3 effectively protects against AF64A-generated cholinotoxicity if administered both 7 days before and 7 days after the AF64A injection. In contrast to these findings, administration of 5 or 10 mg/kg/day C3 or 25 mg/kg/day C3, given 7 days before or 7 days after stereotaxic AF64A injection, did not show cholinoprotective effects. In conclusion, the time-dependent effects of C3 on AF64A-induced cholinergic lesion suggest that C3 may act via the processes of both neuroprotection and neurorepair. Moreover, the effects of C3 depend largely on the administered dose of this low-molecular-weight GAG. The present findings also indicate that C3, administered in the effective concentration and timeframe, may play a pivotal role in the treatment of AD.